Channel Therapeutics Corporation (AMEX:CHRO) shares traded -22.28% lower at $1.43 on Wall Street last session.
CHRO stock price is now -12.84% away from the 50-day moving average and 27.97% away from the 200-day moving average. The market capitalization of the company currently stands at $8.72M.
In other news, Malamut Richard, Director bought 10,400 shares of the company’s stock on Sep 12 ’24. The stock was bought for $9,825 at an average price of $0.94. Upon completion of the transaction, the Director now directly owns 91,565 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 13 ’24, CEO, Pres., CFO, Treas & Secty Francis Knuettel II bought 3,500 shares of the business’s stock. A total of $3,395 was incurred on buying the stock at an average price of $0.97. This leaves the insider owning 547,710 shares of the company worth $0.78 million. A total of 79.64% of the company’s stock is owned by insiders.
During the past 12 months, Channel Therapeutics Corporation has had a low of $0.45 and a high of $3.80. The fifty day moving average price for CHRO is $1.64062 and a two-hundred day moving average price translates $1.11746 for the stock.
The latest earnings results from Channel Therapeutics Corporation (AMEX: CHRO) was released for 2024-12-31. The company reported revenue of $1.82 million for the quarter, compared to $3.88 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -52.95 percent.
